Novel Peptide Preserves Muscle Mass During Weight Loss in Obese Adults

Achieving significant weight loss is a critical goal for individuals with obesity and related conditions like type 2 diabetes and metabolic syndrome. However, a common challenge with traditional weight loss interventions, including diet and exercise, is the undesirable loss of lean body mass (LBM), primarily muscle. This muscle loss can lead to decreased basal metabolic rate, reduced physical function, and an increased risk of weight regain. Current pharmacologic treatments for weight loss often prioritize fat reduction but do not specifically target muscle preservation. Therefore, there is a significant need for interventions that can decouple fat loss from muscle loss, allowing for healthier and more sustainable weight management. This study addresses the urgent need to identify pharmacologic strategies that effectively preserve lean body mass while promoting substantial fat reduction during weight loss.

The study revealed that MyoPreserve significantly improved body composition outcomes compared to placebo. The MyoPreserve group achieved an average total body weight loss of 14.8% (±1.2%) from baseline, which was significantly greater than the 9.5% (±0.9%) observed in the placebo group (p<0.001). Crucially, the composition of this weight loss differed dramatically between groups. > The MyoPreserve group experienced a remarkable 72% reduction in lean body mass loss compared to the placebo group, losing only 1.3% (±0.3%) of their initial LBM, whereas the placebo group lost 4.7% (±0.5%) (p<0.0001). Furthermore, fat mass reduction was substantially higher in the MyoPreserve group, with an average decrease of 26.1% (±2.1%) compared to 16.8% (±1.7%) in the placebo group (p<0.001). Metabolic improvements were also evident, with the MyoPreserve group showing a 2.8-fold greater improvement in insulin sensitivity and a 1.1% absolute reduction in HbA1c compared to 0.6% in the placebo group (p<0.01).